GEn1E Lifesciences
Private Company
Funding information not available
Overview
GEn1E Lifesciences is a private, clinical-stage biotech accelerating first-in-class therapies for inflammatory and rare diseases. Its lead asset, GEn-1124, is a dual p38α:MK2 signal modulator in Phase 2 for ARDS, developed in collaboration with BARDA. The company's core differentiator is its GRID™ AI platform, which enables rapid identification of novel allosteric binding pockets and has propelled its lead program from discovery to Phase 2 in just 2.5 years using seed capital.
Technology Platform
GRID™ AI platform integrating curated biological data with machine learning models to discover novel allosteric binding pockets and accelerate drug discovery and development from target to clinic.
Opportunities
Risk Factors
Competitive Landscape
Competes in the crowded kinase inhibitor space, but aims to differentiate by avoiding the immunosuppressive pitfalls of traditional ATP-competitive inhibitors through allosteric, signal-modifying mechanisms. Faces competition from other biotechs and pharma companies developing therapies for ARDS, chronic inflammation, and oncology.